Tertomotide
- Generic Name
- Tertomotide
- Drug Type
- Biotech
- CAS Number
- 915019-08-8
- Unique Ingredient Identifier
- 55R7RG342O
- Background
Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma). It is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells. It is being developed by Pharmexa A/S.
Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- GemVax & Kael
- Target Recruit Count
- 56
- Registration Number
- NCT06625710
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- GemVax & Kael
- Registration Number
- NCT03959553
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- GemVax & Kael
- Target Recruit Count
- 161
- Registration Number
- NCT02855892
- Locations
- 🇰🇷
Eulji General Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Samsung Pharmaceutical Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT02854072
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷Jeju National University Hospital, Jeju-si, Jeju-do, Korea, Republic of
Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer
- Conditions
- Inoperable Stage III Non-small Cell Lung Cancer
- Interventions
- Drug: normal saline
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Kael-GemVax Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT01579188
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.